New drug classification: treatment with biological products 7 class new medicine (2003 l01261 clinical certificate no. :)

Indications: for the prevention and treatment of venous thrombosis formation

Project progress: the approval documents of clinical trials, have been obtained

Project introduction: thrombosis is caused by a blood clot blood vessel cavity stenosis and occlusion, ischemic infarction in the main viscera dysfunction caused a variety of diseases. Each year, myocardial infarction, cerebral thrombosis, cerebral infarction, coronary heart disease, atherosclerosis and other cardiovascular disease claimed 12 million lives, close to a quarter of all deaths in the world. Hirudin is found that the strongest thrombin inhibitors. Animal experiments and clinical studies have shown that hirudin can efficient anticoagulant, resisting thrombosis, and prevent blood clotting enzyme catalytic of activation and platelet clotting factors such as blood stasis phenomenon further. Compared with the clinical commonly used heparin, hirudin has the advantages of low dosage, bleeding side effect is small, also does not rely on the advantages of the endogenous cofactors.

Domestic recombinant hirudin listed yet. The drug listing will fill the domestic blank, the market prospect is considerable. The current clinical anticoagulants are mainly composed of heparin. But the recombinant hirudin is higher than heparin security. Of recombinant hirudin can be used for renal failure patients with hemodialysis, prevention of thrombosis, and treatment of cardiovascular diseases such as unstable angina, indications, market capacity will increase further.